

DATE:	19 December 2025
TO:	All Healthcare Providers
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL)
RE:	Temporary Resumption of Lipoprotein (a) [Lp(a)] Testing

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective immediately, lipoprotein (a) [Lp(a)] testing has resumed. However, results availability may be delayed.

Why this is important

- An update from the vendor identified that University of Alberta Hospital laboratory will experience interruption to the reagent for Lp(a) testing due to supply chain issues.
- Our team will temporarily consolidate testing at Diagnostic Scientific Centre (DSC) in Calgary.
- Samples collected in Central, Edmonton, and North zone may experience delays in result availability.
- The timeline of this temporary change is unknown. Communication will be provided when the situation changes.
- Previous lab bulletin on “Temporary unavailability of lipoprotein (a) testing” distributed on December 15, 2025 is rescinded.

Action Required

- Be aware that results availability may be delayed.
- No changes in testing methods and reference intervals.
- As a reminder, Lp(a) levels are not influenced by age, sex, fasting state, inflammation, or lifestyle factors, so repeat measurements are not required for risk assessment. Please review the patient chart for previous Lp(a) results before ordering.

Inquiries and feedback may be directed to

- Dr. Albert Tsui, Clinical Biochemist, University of Alberta Hospital, APL, albert.tsui@aplabs.ca
- Dr. Samantha Logan, Clinical Biochemist, Diagnostic Scientific Centre, APL, samantha.logan@aplabs.ca

This bulletin has been reviewed and approved by

- Dr. Carolyn O’Hara, Chief Medical Laboratory Officer, APL